-
公开(公告)号:US20120329794A1
公开(公告)日:2012-12-27
申请号:US12305146
申请日:2007-06-29
IPC分类号: A61K31/416 , A61K31/4439 , C12N9/99 , A61K31/454 , A61P35/00 , A61P35/02 , A61K31/5377 , A61K31/496
CPC分类号: C07D231/56 , A61K31/416 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/5377 , C07D401/06 , C07D403/10 , C07D413/12
摘要: The present invention provides an Abelson kinase (Abl kinase) inhibitor which comprises, as an active ingredient, an indazole derivative represented by Formula (I) (wherein R1 represents substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group) or a pharmaceutically acceptable salt thereof,an Abl kinase inhibitor which comprises, as an active ingredient, an indazole derivative represented by Formula (Ia) [wherein R2 represents CONR4aR4b (wherein R4a and R4b may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, or the like, or R4a and R4b are combined together with the adjacent nitrogen atom thereto to form a substituted or unsubstituted heterocyclic group) or the like, and R3 represents a hydrogen atom, substituted or unsubstituted lower alkyl, or the like] or a pharmaceutically acceptable salt thereof, and the like.
摘要翻译: 本发明提供了一种Abelson激酶(Abl激酶)抑制剂,其包含式(I)表示的吲唑衍生物作为活性成分(其中R 1表示取代或未取代的芳基或取代或未取代的杂环基)或其药学上可接受的盐 其包含作为活性成分的由式(Ia)表示的吲唑衍生物(其中R 2表示CONR 4 aR 4 b(其中R 4a和R 4b可以相同或不同,各自表示氢原子,取代或未取代的低级)的Abl激酶抑制剂 烷基等,或者R4a和R4b与相邻的氮原子一起形成取代或未取代的杂环基)等,R 3表示氢原子,取代或未取代的低级烷基等,或 其药学上可接受的盐等。
-
公开(公告)号:US20120020962A1
公开(公告)日:2012-01-26
申请号:US13225811
申请日:2011-09-06
申请人: Ryuzo UEDA , Kenya SHITARA , Shiro AKINAGA , Rinpei NIWA , Masamichi KOIKE
发明人: Ryuzo UEDA , Kenya SHITARA , Shiro AKINAGA , Rinpei NIWA , Masamichi KOIKE
CPC分类号: C07K16/2866 , A61K2039/505 , C07K2317/24 , Y02A50/41 , Y02A50/412
摘要: The present invention relates to the method for depleting in vivo regulatory T cell, the method for suppressing IL-10 producing activity of regulatory T cell, the method for treating diseases in which pathologic conditions are deteriorated by regulatory T cell and the method for enhancing tumor immunity which comprises administering to a patient a monoclonal antibody which specifically binds to human CC chemokine 4 (CCR4) or the antibody fragment thereof.
摘要翻译: 本发明涉及体内调节性T细胞的消耗方法,抑制调节性T细胞的IL-10产生活性的方法,通过调节性T细胞治疗病变状态的疾病的治疗方法及增强肿瘤的方法 其包括向患者施用特异性结合人CC趋化因子4(CCR4)或其抗体片段的单克隆抗体。
-
公开(公告)号:US20100166847A1
公开(公告)日:2010-07-01
申请号:US12656487
申请日:2010-02-01
申请人: Yasuki Kato , Masahiro Yamauchi , Hiroko Kusano , Takeshi Iwata , Takaaki Uochi , Shiro Akinaga
发明人: Yasuki Kato , Masahiro Yamauchi , Hiroko Kusano , Takeshi Iwata , Takaaki Uochi , Shiro Akinaga
IPC分类号: A61K9/127 , A61K38/02 , A61K31/7088
CPC分类号: A61K9/5123 , A61K9/127 , A61K9/1271 , A61K9/1272 , A61K9/141 , A61K9/146 , A61K9/5015 , A61K9/5192 , A61K31/7088 , A61K47/6911 , B01J13/12
摘要: An object of the present invention is to provide a safe, convenient and efficient method for coating fine particles with lipid membrane.There is provided a method for coating fine particles with lipid membrane, characterized in that, the rate of a polar organic solvent in an aqueous solution containing the polar organic solvent where the fine particles are dispersed and lipid is dissolved, is decreased.
摘要翻译: 本发明的目的是提供一种安全,方便和有效的用脂质膜涂覆微粒的方法。 提供了一种用脂质膜包覆微粒的方法,其特征在于,含有分散有微粒的极性有机溶剂和溶解脂质的水溶液中的极性有机溶剂的比例降低。
-
公开(公告)号:US07678415B2
公开(公告)日:2010-03-16
申请号:US10398222
申请日:2001-10-04
申请人: Yasuki Kato , Masahiro Yamauchi , Hiroko Kusano , Takeshi Iwata , Takaaki Uochi , Shiro Akinaga
发明人: Yasuki Kato , Masahiro Yamauchi , Hiroko Kusano , Takeshi Iwata , Takaaki Uochi , Shiro Akinaga
CPC分类号: A61K9/5123 , A61K9/127 , A61K9/1271 , A61K9/1272 , A61K9/141 , A61K9/146 , A61K9/5015 , A61K9/5192 , A61K31/7088 , A61K47/6911 , B01J13/12
摘要: An object of the present invention is to provide a safe, convenient and efficient method for coating fine particles with lipid membrane.There is provided a method for coating fine particles with lipid membrane, characterized in that, the rate of a polar organic solvent in an aqueous solution containing the polar organic solvent where the fine particles are dispersed and lipid is dissolved, is decreased.
摘要翻译: 本发明的目的是提供一种安全,方便和有效的用脂质膜涂覆微粒的方法。 提供了一种用脂质膜包覆微粒的方法,其特征在于,含有分散有微粒的极性有机溶剂和溶解脂质的水溶液中的极性有机溶剂的比例降低。
-
公开(公告)号:US20090247522A1
公开(公告)日:2009-10-01
申请号:US12427847
申请日:2009-04-22
申请人: Shinji Nara , Hiroshi Nakagawa , Yutaka Kanda , Takayuki Nakashima , Shiro Soga , Jiro Kajita , Jun-ichi Saito , Yukimasa Shiotsu , Shiro Akinaga
发明人: Shinji Nara , Hiroshi Nakagawa , Yutaka Kanda , Takayuki Nakashima , Shiro Soga , Jiro Kajita , Jun-ichi Saito , Yukimasa Shiotsu , Shiro Akinaga
IPC分类号: A61K31/5377 , A61K31/12 , A61K31/216 , A61K31/165 , A61K31/44 , A61K31/495 , A61K31/445 , A61K31/40 , A61K31/496 , A61K31/47 , A61K31/5375 , A61P35/00
CPC分类号: C07D211/42 , A61K31/12 , A61K31/165 , A61K31/216 , A61K31/40 , A61K31/4406 , A61K31/4409 , A61K31/445 , A61K31/451 , A61K31/495 , A61K31/506 , A61K31/5375 , A61K31/5377 , C07C49/84 , C07C69/738 , C07C205/45 , C07C235/78 , C07D207/08 , C07D207/12 , C07D207/27 , C07D211/22 , C07D211/52 , C07D211/54 , C07D211/58 , C07D211/60 , C07D211/62 , C07D213/40 , C07D213/50 , C07D217/06 , C07D239/42 , C07D241/08 , C07D295/088 , C07D295/185 , C07D307/46 , C07D307/52 , C07D307/54 , C07D317/60 , C07D333/22 , C07D333/24 , C07D409/10
摘要: The present invention provides Hsp90 family protein inhibitors comprising, as an active ingredient, a benzoyl compound represented by general formula (I): (wherein n represents an integer of 0 to 10; R1 represents substituted or unsubstituted lower alkoxy, substituted or unsubstituted lower alkoxycarbonyl, CONR7R8 or the like; R2 represents substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic group or the like; R3 and R5, which may be the same or different, each represent a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl or the like; and R4 and R6, which may be the same or different, each represent a hydrogen atom, halogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl or the like) or a prodrug thereof, or a pharmaceutically acceptable salt of said benzoyl compound or said prodrug.
摘要翻译: 本发明提供Hsp90家族蛋白质抑制剂,其包含作为活性成分的通式(I)表示的苯甲酰基化合物:(其中n表示0〜10的整数; R 1表示取代或未取代的低级烷氧基,取代或未取代的低级烷氧基羰基 ,CONR7R8等; R2表示取代或未取代的芳基,取代或未取代的芳族杂环基等; R3和R5可相同或不同,分别表示氢原子,取代或未取代的低级烷基,取代或未取代的 未取代的低级烯基等;以及可以相同或不同的R 4和R 6各自表示氢原子,卤素,取代或未取代的低级烷基,取代或未取代的芳基等)或其前药,或药学上 所述苯甲酰化合物或所述前药的可接受的盐。
-
公开(公告)号:US06953785B2
公开(公告)日:2005-10-11
申请号:US10258454
申请日:2001-04-24
申请人: Yoji Ino , Nobuyoshi Amishiro , Mayumi Miyata , Tsutomu Agatsuma , Kozue Muramatsu , Takeshi Takahashi , Shiro Akinaga , Chikara Murakata
发明人: Yoji Ino , Nobuyoshi Amishiro , Mayumi Miyata , Tsutomu Agatsuma , Kozue Muramatsu , Takeshi Takahashi , Shiro Akinaga , Chikara Murakata
IPC分类号: A61P5/24 , A61P5/32 , A61P13/08 , A61P15/00 , A61P35/00 , A61P43/00 , C07J41/00 , C07J43/00 , A61K31/56 , A61K31/58 , C07J3/00 , C07J17/00
摘要: Provided is steroid sulfatase inhibitors comprising, as the active ingredient, an estra-1,3,5(10)-triene derivative which is represented by formula (I): {wherein R1 and R2 are the same or different and represent a hydrogen atom, a lower alkyl group or, etc.; R3 represents a hydrogen atom etc.; R4 represents a hydrogen atom etc.; R5 represents a hydrogen atom etc.; R6 represents a cyano group, an amino group, COR53 (wherein R53 represents a substituted lower alkyl group etc.), a substituted or unsubstituted aryl group, a substituted or unsubstituted heterocyclic group, etc}, or pharmaceutically acceptable salts thereof.
摘要翻译: 提供了类固醇硫酸酯酶抑制剂,其包含作为活性成分的由式(I)表示的雌-1,3,5(10) - 三烯衍生物:其中R 1和R 2 > 2相同或不同,表示氢原子,低级烷基等。 R 3表示氢原子等; R 4表示氢原子等; R 5表示氢原子等; R 6表示氰基,氨基,COR 53(其中R 53表示取代的低级烷基等),取代的 或未取代的芳基,取代或未取代的杂环基等)或其药学上可接受的盐。
-
公开(公告)号:US06806266B1
公开(公告)日:2004-10-19
申请号:US10030618
申请日:2002-01-11
申请人: Fumihiko Kanai , Nobuyoshi Amishiro , Yushi Kitamura , Chikara Murakata , Tadakazu Akiyama , Shiro Akinaga , Eiichi Fuse , Takashi Kuwabara , Kenichi Yasoshima
发明人: Fumihiko Kanai , Nobuyoshi Amishiro , Yushi Kitamura , Chikara Murakata , Tadakazu Akiyama , Shiro Akinaga , Eiichi Fuse , Takashi Kuwabara , Kenichi Yasoshima
IPC分类号: C07D49822
CPC分类号: C07D498/22 , A61K31/553
摘要: The present invention provides an antitumor agent comprising a staurosporin derivative or a pharmaceutically acceptable salt thereof, as an active ingredient, which is represented by the general formula (I): wherein R1 represents hydrogen, hydroxy or lower alkoxy, R2 and R3 are the same or different and represent hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted aryl, a substituted or unsubstituted heterocyclic group, halogen, nitro, formyl, etc., R4 represents hydrogen, etc., R5 represents NR11AR12A (wherein R11A and R12A represent hydrogen, substituted or unsubstituted lower alkyl, etc.), provided that R2 and R3 are not simultaneously hydrogen.
摘要翻译: 本发明提供包含星形孢菌素衍生物或其药学上可接受的盐作为活性成分的抗肿瘤剂,其由通式(I)表示:其中R 1表示氢,羟基或低级烷氧基,R 2 和R 3相同或不同,表示氢,取代或未取代的烷基,取代或未取代的低级烯基,取代或未取代的低级炔基,取代或未取代的芳基,取代或未取代的杂环基,卤素,硝基,甲酰基, 等等,R 4表示氢等,R 5表示NR 11A R 12A(其中R 11A和R 12A表示氢,取代或未取代的低级烷基等), 条件是R 2和R 3不同时为氢。
-
公开(公告)号:US06492392B1
公开(公告)日:2002-12-10
申请号:US09481542
申请日:2000-01-12
申请人: Yutaka Kanda , Rieko Tanaka , Mitsunobu Hara , Jun Eishima , Shiro Akinaga , Tadashi Ashizawa
发明人: Yutaka Kanda , Rieko Tanaka , Mitsunobu Hara , Jun Eishima , Shiro Akinaga , Tadashi Ashizawa
IPC分类号: A61K31445
CPC分类号: C07D401/14 , C07D231/12 , C07D233/56 , C07D249/08 , C07D401/06 , C07D405/14 , C07D409/14
摘要: The present invention provides 2-piperidone compounds or pharmaceutically acceptable salts thereof, which have a potent activity of inhibiting the proliferation of tumor cells and thus are useful as medicaments, as well as antitumor agents containing these compounds. The 2-piperidone compound is represented by the following formula (I): wherein R1 represents —(CH2)nR1a {wherein n is an integer of from 0 to 5, and R1a represents amino, lower alkylamino, di(lower alkyl)amino, substituted or unsubstituted aryl, or a substituted or unsubstituted heterocyclic group}, and R2 and R3 independently represent lower alkyl which may be substituted by lower alkoxycarboyl; lower alkenyl, aralkyl or lower alkynyl which may be substituted by substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group; substituted or unsubstituted aryl; or a substituted or unsubstituted heterocyclic group.
摘要翻译: 本发明提供了具有抑制肿瘤细胞增殖的有效活性的2-哌啶酮化合物或其药学上可接受的盐,因此可用作药物,以及含有这些化合物的抗肿瘤剂。 2-哌啶酮化合物由下式(I)表示:其中R1表示 - (CH2)nR1a {其中n为0-5的整数,R1a表示氨基,低级烷基氨基,二(低级烷基)氨基,取代的 或未取代的芳基,或取代或未取代的杂环基},R2和R3独立地表示可以被低级烷氧基羰基取代的低级烷基; 可被取代或未取代的芳基或取代或未取代的杂环基取代的低级烯基,芳烷基或低级炔基; 取代或未取代的芳基; 或取代或未取代的杂环基。
-
公开(公告)号:US06316491B1
公开(公告)日:2001-11-13
申请号:US09091752
申请日:1998-06-24
申请人: Yoji Ino , Nobuyoshi Amishiro , Mayumi Miyata , Chikara Murakata , Harumi Ogawa , Tadakazu Akiyama , Shiro Akinaga , Shiro Soga , Yukimasa Shiotsu
发明人: Yoji Ino , Nobuyoshi Amishiro , Mayumi Miyata , Chikara Murakata , Harumi Ogawa , Tadakazu Akiyama , Shiro Akinaga , Shiro Soga , Yukimasa Shiotsu
IPC分类号: A61K3135
CPC分类号: C07D493/04 , C07D313/00
摘要: Radioicol derivatives represented by the following formula (I) having tyrosine kinase inhibition activity or pharmacologically acceptable salts thereof: wherein R1 and R2 are the same or different, and each represents hydrogen, alkanoyl, alkenoyl, tert-butyldiphenylsilyl or tert-butyldimethylsilyl; R3 represents Y—R5 (wherein Y represents substituted or unsubstituted alkylene; and R5 represents CONR6R7 (wherein R6 represents hydrogen, hydroxyl, substituted or unsubstituted lower alkyl, substituted or unsubstituted higher alkyl, and the like; R7 represents hydroxyl, substituted lower alkyl, and the like), CO2R12 (wherein R12 represents substituted lower alkyl, substituted or unsubstituted higher alkyl, and the like), and the like) and the like; X represents halogen or is combined together with R4 to represent a single bond; and R4 is combined together with X to represent a single bond, or represents hydrogen, alkanoyl, and the like.
摘要翻译: 由具有酪氨酸激酶抑制活性的下式(I)表示的放射性标记衍生物或其药理学上可接受的盐:其中R1和R2相同或不同,并且各自表示氢,烷酰基,烯酰基,叔丁基二苯基甲硅烷基或叔丁基二甲基甲硅烷基; R3表示Y-R5(其中Y表示取代或未取代的亚烷基; R5表示CONR6R7(其中R6表示氢,羟基,取代或未取代的低级烷基,取代或未取代的高级烷基等; R7表示羟基,取代的低级烷基, 等),CO 2 R 12(其中R 12表示取代的低级烷基,取代或未取代的高级烷基等)等)等; X表示卤素或与R 4一起表示单键; 并且R 4与X结合以表示单键,或表示氢,烷酰基等。
-
公开(公告)号:US06262043B1
公开(公告)日:2001-07-17
申请号:US09548930
申请日:2000-04-13
申请人: Yoji Ino , Nobuyoshi Amishiro , Taisuke Nakata , Hiroyuki Ishida , Shiro Akinaga , Chikara Murakata , Pui-Kai Li
发明人: Yoji Ino , Nobuyoshi Amishiro , Taisuke Nakata , Hiroyuki Ishida , Shiro Akinaga , Chikara Murakata , Pui-Kai Li
IPC分类号: A61K3156
CPC分类号: C07J3/00
摘要: Estra-1,3,5(10),16-tetraene derivatives represented by the following formula (I): (wherein R1 represents hydroxy, alkoxy, or NR2R3 (wherein R2 and R3 are the same or different, and each represents hydrogen, straight-chain lower alkyl having 1 to 3 carbon atoms, or branched-chain lower alkyl having 3 to 8 carbon atoms)), or pharmaceutically acceptable salts thereof.
摘要翻译: 由下式(I)表示的Estra-1,3,5(10),16-四烯衍生物:(其中R1表示羟基,烷氧基或NR2R3(其中R2和R3相同或不同,各自表示氢, 具有1至3个碳原子的直链低级烷基或具有3至8个碳原子的支链低级烷基))或其药学上可接受的盐。
-
-
-
-
-
-
-
-
-